NCT04786340View on ClinicalTrials.gov

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

December 8, 2022

Study Completion Date

December 8, 2022

Conditions

Painful Diabetic NeuropathyDiabetes Mellitus

Interventions

DRUG

Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution

WST-057

DRUG

Placebo: WST-057 4mL topical solution

Placebo

Trial Locations (1)

23510-1001

Eastern Virginia Medical School, Norfolk

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Eastern Virginia Medical School

OTHER

lead

WinSanTor, Inc

INDUSTRY

NCT04786340 - A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy | Biotech Hunter | Biotech Hunter